Deka Bank Deutsche Girozentrale Beam Therapeutics Inc. Transaction History

Deka Bank Deutsche Girozentrale

$54.1 Billion
Q4 2024

A detailed history of Deka Bank Deutsche Girozentrale transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Deka Bank Deutsche Girozentrale holds 50,000 shares of BEAM stock, worth $1.38 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

50,000

Previous 50,000 -0.0%

Holding current value

$1.38 Million

Previous $1.7 Million 5.24%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$23.01 - $32.46 $115,050 - $162,300	-5,000 Reduced 9.09%	50,000 $1.2 Million
Q1 2023 Apr 24, 2023	BUY	$30.15 - $48.79 $301,500 - $487,900	10,000 Added 22.22%	55,000 $1.66 Million
Q4 2022 Feb 01, 2023	BUY	$36.73 - $51.6 $734,599 - $1.03 Million	20,000 Added 80.0%	45,000 $1.74 Million
Q3 2022 Nov 02, 2022	BUY	$39.79 - $70.31 $437,690 - $773,410	11,000 Added 78.57%	25,000 $1.2 Million
Q2 2022 Aug 03, 2022	SELL	$29.86 - $62.36 $53,748 - $112,248	-1,800 Reduced 11.39%	14,000 $566,000
Q1 2022 Apr 28, 2022	BUY	$53.73 - $82.16 $5,373 - $8,216	100 Added 0.64%	15,800 $939,000
Q4 2021 Feb 02, 2022	BUY	$68.02 - $99.06 $27,208 - $39,624	400 Added 2.61%	15,700 $1.24 Million
Q3 2021 Oct 22, 2021	BUY	$84.37 - $133.6 $843,700 - $1.34 Million	10,000 Added 188.68%	15,300 $1.33 Million
Q2 2021 Aug 05, 2021	SELL	$64.12 - $128.71 $1.03 Million - $2.06 Million	-16,000 Reduced 75.12%	5,300 $587,000
Q1 2021 Apr 28, 2021	BUY	$71.28 - $120.75 $92,664 - $156,975	1,300 Added 6.5%	21,300 $1.61 Million
Q4 2020 Mar 12, 2021	BUY	$22.24 - $95.63 $444,799 - $1.91 Million	20,000 New	20,000 $1.77 Million

Others Institutions Holding BEAM

# of Institutions

240

Shares Held

76.3M

Call Options Held

438K

Put Options Held

232K

View Full List

About Beam Therapeutics Inc.

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.95B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

More about BEAM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.

Account

Deka Bank Deutsche Girozentrale Beam Therapeutics Inc. Transaction History